ReviewFrontiers in aging2026
Targeting innate immunity to modulate bone metabolism: a novel strategy for osteoporosis treatment.
Review in Frontiers in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a systemic metabolic bone disorder characterized by reduced bone mass and impaired microarchitecture, with its core pathological mechanism being an imbalance between bone formation and resorption. Traditional therapies targeting osteoblast/osteoclast function have limited efficacy and safety concerns. Recent osteoimmunology advances reveal that the innate immune system regulates bone homeostasis via intercellular interactions, cytokine networks, and metabolic reprogramming. This systematic review examines the roles of innate immune cells (macrophages, neutrophils, NK cells, DCs), complement system, and emerging pathways (trained immunity, mitochondrial symbiosis disruption) in osteoporosis. It summarizes therapeutic strategies (immunometabolic modulators, complement antagonists, cytokine-targeted drugs, TCM components) and outlines challenges (target specificity, clinical translation) and future directions, providing theoretical foundations for novel OP treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.